Author

L. Nastoupil

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cell type annotation· 3 Organism:human· 3 Research Focus:differential expression· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

H. Yang· 3 shared M. R. Green· 3 shared S. Neelapu· 3 shared E. Dai· 2 shared E. Rojas· 2 shared F. Samaniego· 2 shared J. Henderson· 2 shared J. Westin· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

H. Yang

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CREBBP lysine acetyltransferase domain mutations create zombie enzymes that alter chromatin loading dynamics and prevent EP300 redundancy

H. Yang, W. Zhang, V. Ravanmehr, A. Mechaly, L. Regad, A. Haouz, R. Chen, J. Henderson, E. Rojas, A. Wilson, S. Parsons, L. Nastoupil, R. E. Davis, Q. Deng, F. Samaniego, , M. R. Green

The paper shows that CREBBP mutations disrupt chromatin loading dynamics and EP300 redundancy, creating zombie enzymes that impair enhancer activation in GC B-cells and lymphoma.

bioRxiv · Sep 5, 2023 · PreprintCancer Biology

CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin

P. K. Reville, I. N. Sheikh, A. Choi, E. Dai, J. Henderson, X. Li, E. Rojas, C. C. Le, C. Okwuchi, M. Devonish, R. Carrio, N. Pate, K. Malley, D. Bangari, J.-A. Givigan, , M. R. Green

The paper identifies dysfunctional CD8 CAR T-cells in rrLBCL tumors and shows that pegenzileukin mitigates this dysfunction, improving CAR T-cell responses.

bioRxiv · Aug 28, 2023 · PreprintImmunology

Immune microenvironment subtypes and association with tumor cell mutations and antigen expression in follicular lymphoma.

G. Han, Q. Deng, E. Dai, M. Dang, J. Ma, H. Yang, O. Kudryashova, M. Meerson, S. Isaev, N. Kotlov, K. Nomie, A. Bagaev, S. Parmar, F. Hagemeister, S. Ahmed, , M. R. Green

The paper identifies immune microenvironment subtypes in follicular lymphoma linked to tumor mutations and antigen expression, informing potential immunotherapeutic strategies.

bioRxiv · Apr 27, 2021 · PreprintCancer Biology

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

P. Mondello, S. Tadros, M. Teater, L. Fontan, A. Chang, N. Jain, S. Singh, M. C. J. Ma, H. Yang, E. Toska, S. Alig, M. Durant, E. de Stanchina, A. Mottok, L. Nastoupil, , M. Green

This paper shows that HDAC3 inhibitors reverse CREBBP mutation-driven epigenetic changes in lymphoma, inhibiting tumor growth and restoring immune surveillance.

bioRxiv · Jan 27, 2019Cancer Biology